DelveInsight has launched a new report on “Adult Growth Hormone Deficiency – Market Insights, Epidemiology, and Market Forecast-2032” that delivers an in-depth understanding of the Adult Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent advancements in the Adult Growth Hormone Deficiency Market:
- FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
- The U.S. Food and Drug Administration granted approval for Sogroya (somapacitan) intended for adults facing growth hormone deficiency. Sogroya stands out as the inaugural human growth hormone (hGH) treatment designed specifically for adult patients, necessitating only a weekly subcutaneous injection. Other FDA-endorsed hGH treatments for adults dealing with growth hormone deficiency require daily administration.
Some of the key facts of the Adult Growth Hormone Deficiency Market Report:
Adult Growth Hormone Deficiency (AGHD), a medical condition wherein growth hormone secretion falls below the normal levels, results in a clinical syndrome characterized by alterations in body composition, diminished aerobic exercise capacity and quality of life, and adverse changes in lipid and carbohydrate metabolism and cardiovascular function.
- According to NORD Growth hormone deficiency affects males and females equally except for AGHD III which affects only males. However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. 73% of patients with idiopathic AGHD in the NCGS were male. Additionally, patients with AGHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.
- According to D B Allen et al., about 15%-20% of the cases represent the transition of childhood GH deficiency into adulthood.
- According to Shimon et al. (2019), In the USA, the incidence of AGHD is approximately 6000 new cases per annum, with an estimated 50,000 diagnosed adults. In Europe, the annual incidence is 12–19 cases per million.
Key benefits of the report:
- Adult Growth Hormone Deficiency market report covers a descriptive overview and comprehensive insight of the Adult Growth Hormone Deficiency Epidemiology and Adult Growth Hormone Deficiency market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Adult Growth Hormone Deficiency market report provides insights on the current and emerging therapies.
- Adult Growth Hormone Deficiency market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Adult Growth Hormone Deficiency market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adult Growth Hormone Deficiency market.
Got queries? Click here to know more about the Adult Growth Hormone Deficiency Market Landscape.
Adult Growth Hormone Deficiency Overview
Adult growth hormone deficiency (AGHD) refers to a medical condition characterized by a shortage of growth hormone (GH) in adults. Growth hormone, produced by the pituitary gland, plays a crucial role in growth during childhood and adolescence, but it also continues to have important effects on metabolism and other body functions throughout adulthood.
AGHD can occur due to various causes, including damage to the pituitary gland, tumors, radiation therapy, or as a result of certain genetic conditions. Sometimes, it can also be idiopathic, meaning the exact cause is unknown.
Adult growth hormone deficiency Symptoms:
Decreased Bone Density: Lower levels of growth hormone can lead to reduced bone mineral density, which may increase the risk of osteoporosis and fractures.
Changes in Body Composition: Individuals with AGHD may experience increased fat, especially around the waist, and reduced muscle mass.
Fatigue and Decreased Energy Levels: Feeling tired and lacking energy despite adequate rest and sleep is common.
Changes in Lipid Profile: AGHD might lead to unfavorable changes in cholesterol levels, including higher LDL (bad cholesterol) and lower HDL (good cholesterol).
Impaired Psychological Well-being: Some individuals may experience symptoms of depression, anxiety, or social withdrawal.
Impaired Cognitive Function: Decreased memory and cognitive functions have been reported in some cases of AGHD.
Treatment for adult growth hormone deficiency typically involves hormone replacement therapy using synthetic growth hormone. This treatment aims to restore hormone levels to normal ranges and alleviate the symptoms associated with the deficiency. However, treatment plans should be individualized and monitored by healthcare professionals to ensure safety and effectiveness. Regular follow-ups and monitoring are essential to adjust the treatment as needed and manage any potential side effects.
Adult Growth Hormone Deficiency Market
The dynamics of the Adult Growth Hormone Deficiency market is anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as Ascendis Pharma, Genexine, OPKO Health, and others during the forecasted period 2019-2032.
Adult Growth Hormone Deficiency Clinical Trial, Therapies and Key Companies
- TransCon hGH: Ascendis Pharma
- HyTropin (GX-H9): Genexine
- Somatrogon: OPKO Health
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Adult Growth Hormone Deficiency Patient Share (%) Overview at a Glance
5. Adult Growth Hormone Deficiency Market Overview at a Glance
6. Adult Growth Hormone Deficiency Disease Background and Overview
7. Adult Growth Hormone Deficiency Epidemiology and Patient Population
8. Country-Specific Patient Population of Adult Growth Hormone Deficiency
9. Adult Growth Hormone Deficiency Current Treatment and Medical Practices
10. Unmet Needs
11. Adult Growth Hormone Deficiency Emerging Therapies
12. Adult Growth Hormone Deficiency Market Outlook
13. Country-Wise Adult Growth Hormone Deficiency Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Adult Growth Hormone Deficiency Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Adult Growth Hormone Deficiency Market Outlook 2032.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States